The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting
2024

FDG PET Scans Help Predict Survival in Advanced Breast Cancer Patients

Sample size: 39 publication Evidence: moderate

Author Information

Author(s): Kubeczko Marcin, Polakiewicz-Gilowska Anna, D’Amico Andrea, Chrabański Olgierd, Świderska Katarzyna, Chmielik Ewa, Blamek Sławomir, Handkiewicz-Junak Daria, Jarząb Michał

Primary Institution: Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland

Hypothesis

Can FDG-PET-CT scans before treatment with CDK4/6 inhibitors predict patient outcomes in advanced breast cancer?

Conclusion

FDG-PET-CT scans taken before starting CDK4/6 inhibitors can effectively predict progression-free survival in patients with advanced breast cancer.

Supporting Evidence

  • Patients with low SUVmax had a median progression-free survival of 30.7 months.
  • Patients with high SUVmax had a median progression-free survival of 13.0 months.
  • The 2-year progression-free survival was 76.2% for the low SUVmax group.

Takeaway

Doctors can use special scans to see how well patients with advanced breast cancer might do with certain treatments, helping them make better choices.

Methodology

This study analyzed data from patients treated with CDK4/6 inhibitors in the second-line setting, focusing on the prognostic value of FDG-PET-CT scans.

Limitations

The study is retrospective and includes a relatively small number of patients.

Participant Demographics

The median age of participants was 63 years, with a mix of de novo metastatic and oligometastatic disease.

Statistical Information

P-Value

0.038

Confidence Interval

[95% CI 25.6 months - not reached]

Statistical Significance

p = 0.038

Digital Object Identifier (DOI)

10.3389/fonc.2024.1454844

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication